Physician profile
Amanda Silverman
NPI 1699290312
$1,301.39
in general payments reported to CMS, 2019-2025
12 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $321 · 2023: $271 · 2024: $124 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.76 | 2021-2024 | |
| Abbvie INC. | $266.81 | 2021-2023 | |
| Glaxosmithkline, LLC. | $213.77 | 2023-2025 | Nucala, Trelegy Ellipta |
| Mayne Pharma Commercial LLC | $115.39 | 2022-2025 | |
| Coopersurgical, INC. | $97.56 | 2022-2025 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $96.60 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $78.52 | 2021-2022 | |
| Sage Therapeutics, LLC | $57.09 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $43.81 | 2021-2022 | |
| Exeltis, USA INC. | $24.87 | 2025 | Slynd |
| Urovant Sciences INC | $19.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.